CKD stage | CKD stage I | CKD stage II | CKD stage III | CKD stage IV+V |
---|---|---|---|---|
Number of patients | 44 | 11 | 13 | 13 |
% of total patients | 54.3% | 13.6% | 16.0% | 16.0% |
Median GFR (IQR 25th-75th percentile) | 141.3 (105.1-161.9) | 71.3 (65.8-82.8) | 43.5 (36.4-5.9) | 15.3 (11.7-20.4) |
Renal acidosis | ||||
Overall treated | 11.4% | 0.0% | 30.8% | 23.1% |
Treated with bicarbonate (%) | 2.3% | 0.0% | 23.1% | 23.1% |
Treated with potassium/sodium citrate (%) | 9.1% | 0.0% | 7.7% | 0.0% |
Hypertension | ||||
Patients on any BP meds (%) | 54.5% | 72.7% | 46.2% | 76.9% |
Patients on ACE-I or ARB (%) | 43.2% | 72.7% | 53.8% | 46.2% |
Patients on non-ACE-I (diuretics, Ca-channel blocker etc.) (%) | 18.2% | 27.3% | 15.4% | 53.8% |
Patients on multiple therapies (%) | 22.7% | 36.4% | 15.4% | 23.1% |
Steroid therapy | ||||
% of patients on corticosteroid medications | 18.2% | 18.2% | 7.7% | 7.7% |
% Renal osteodystrophy treated with | ||||
calcium containing phosphate binders | 0.0% | 9.1% | 15.4% | 46.2% |
non-calcium containing phosphate binders | 0.0% | 0.0% | 0.0% | 15.4% |
vitamin D analog | 6.8% | 9.1% | 0.0% | 46.2% |
active vitamin D analog | 0.0% | 9.1% | 30.8% | 53.8% |
Abnormally high PTH (N=1.6-6.9 pmol/L) | 6.8% | 36.4% | 69.2% | 84.6% |
Abnormally high FGF-23 (N=10-50 pg/mL) | 13.6% | 27.3% | 53.8% | 92.3% |
Abnormally high phosphate (N=0.80-1.33 mmol/L) | 40.9% | 45.5% | 15.4% | 84.6% |